These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 27228211)

  • 1. Further understanding of the pathology of glioma: implications for the clinic.
    Camelo-Piragua S; Kesari S
    Expert Rev Neurother; 2016 Sep; 16(9):1055-65. PubMed ID: 27228211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular genetics of gliomas.
    Appin CL; Brat DJ
    Cancer J; 2014; 20(1):66-72. PubMed ID: 24445767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathology and Genetics of Gliomas.
    Komori T; Muragaki Y; Chernov MF
    Prog Neurol Surg; 2018; 31():1-37. PubMed ID: 29393190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker-driven diagnosis of diffuse gliomas.
    Appin CL; Brat DJ
    Mol Aspects Med; 2015 Nov; 45():87-96. PubMed ID: 26004297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular genetics of ependymomas and pediatric diffuse gliomas: a short review.
    Nobusawa S; Hirato J; Yokoo H
    Brain Tumor Pathol; 2014 Oct; 31(4):229-33. PubMed ID: 25182241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular classification defines 4 prognostically distinct glioma groups irrespective of diagnosis and grade.
    Mur P; Mollejo M; Hernández-Iglesias T; de Lope ÁR; Castresana JS; García JF; Fiaño C; Ribalta T; Rey JA; Meléndez B
    J Neuropathol Exp Neurol; 2015 Mar; 74(3):241-9. PubMed ID: 25668564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of gliomas: from morphology to molecules.
    Ferris SP; Hofmann JW; Solomon DA; Perry A
    Virchows Arch; 2017 Aug; 471(2):257-269. PubMed ID: 28674742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
    Macaulay RJ
    Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular pathways in gliomagenesis and their relevance to neuropathologic diagnosis.
    Appin CL; Brat DJ
    Adv Anat Pathol; 2015 Jan; 22(1):50-8. PubMed ID: 25461780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glioma.
    Weller M; Wick W; Aldape K; Brada M; Berger M; Pfister SM; Nishikawa R; Rosenthal M; Wen PY; Stupp R; Reifenberger G
    Nat Rev Dis Primers; 2015 Jul; 1():15017. PubMed ID: 27188790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in subtyping tumors of the central nervous system using molecular data.
    Schittenhelm J
    Expert Rev Mol Diagn; 2017 Jan; 17(1):83-94. PubMed ID: 27893285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.
    Wiestler B; Capper D; Holland-Letz T; Korshunov A; von Deimling A; Pfister SM; Platten M; Weller M; Wick W
    Acta Neuropathol; 2013 Sep; 126(3):443-51. PubMed ID: 23904111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
    Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
    Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics.
    Velázquez Vega JE; Brat DJ
    Adv Anat Pathol; 2018 May; 25(3):143-171. PubMed ID: 29521646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Input of molecular analysis in medical management of primary brain tumor patients.
    Idbaih A; Duran-Peña A; Bonnet C; Ducray F
    Rev Neurol (Paris); 2015; 171(6-7):457-65. PubMed ID: 26026669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
    Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
    Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated molecular analysis suggests a three-class model for low-grade gliomas: a proof-of-concept study.
    Marko NF; Prayson RA; Barnett GH; Weil RJ
    Genomics; 2010 Jan; 95(1):16-24. PubMed ID: 19835948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cortical ependymoma or monomorphous angiocentric glioma?
    Lum DJ; Halliday W; Watson M; Smith A; Law A
    Neuropathology; 2008 Feb; 28(1):81-6. PubMed ID: 18021197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.